X-Aptamer Selection Kit

X 适体选择试剂盒

• 批准号: 8980090
• 负责人: Curtis Honming Lam
• 金额: $ 70.06万
• 依托单位: AM BIOTECHNOLOGIES, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8980090
• 关键词: Adsorption; Affinity; Amino Acids; Antibodies; Arginine; Binding; Bioinformatics; Biological Sciences; Boronic Acids; Caliber; Characteristics; Chemicals; Cleaved cell; DNA; Data; Diagnostic tests; Disease; Environment; Equipment; Exhibits; Folic Acid; Guanidines; Indoles; Laboratories; Lead; Libraries; Marketing; Microspheres; Modification; Myristates; Nature; Nucleosides; Oligonucleotides; Outcome; Penetration; Phase; Phenols; Polystyrenes; Price; Process; Proteins; Protocols documentation; Reagent; Resources; Scientist; Small Business Innovation Research Grant; Solvents; Specificity; Swelling; Techniques; Technology; Testing; Time; Tryptophan; Tyrosine; aptamer; base; combinatorial; commercial application; commercialization; cost; design; drug candidate; functional group; improved; interest; next generation; next generation sequencing; novel; phosphorodithioic acid; polymethacrylate; prototype; public health relevance; scaffold; skills; small molecule; success

 DESCRIPTION (provided by applicant): The X-Aptamer Selection Kit (XASK) makes aptamers much more accessible to the life science market. The low-priced kit greatly minimizes the expertise and equipment required to perform aptamer selections; thus, enabling virtually any scientist with basic laboratory skills to rapidly develop his or her own synthetic next generation X-Aptamer (XA) affinity reagents. The Phase I SBIR successfully answered several fundamental questions associated with the bead-based selection technology underlying the XASK. It also conclusively demonstrated the feasibility of the kit as a commercial product. Several independent users successfully selected X-Aptamers using XASK prototypes, which far exceeded the anticipated outcome from Phase I. X-Aptamers are chemically-modified DNA affinity agents that utilize amino acid functional groups and even small molecules to enhance interaction with targets. XAs routinely exhibit nanomolar to picomolar binding affinity as well as excellent specificity, making them a promising synthetic alternative to antibodies. AM Biotech has developed a rapid, single-cycle XA discovery process that is not based on SELEX. The process is performed in two easy steps using bead-based oligonucleotide libraries and standard laboratory equipment that enable packaging the discovery processes into XASK. The Phase II SBIR will focus on; 1) enhancing the quality of the critically important bead-based libraries, and 2) optimizing the bead-based selection process to improve the success rate to >85%. The XASK is a revolutionary product that will disrupt the aptamer market and will begin to make inroads into the antibody market. AM Biotech believes that the XASK and X-Aptamers are poised for strong market penetration that will help to pull aptamers into many commercial applications.

 描述（由申请人提供）：X-Aptamer选择试剂盒（XASK）使适体更容易进入生命科学市场。低价的试剂盒大大减少了进行适体选择所需的专业知识和设备;因此，几乎任何具有基本实验室技能的科学家都可以快速开发自己的合成下一代X-适体（XA）亲和试剂。第一阶段SBIR成功地回答了与XASK基础的基于微珠的选择技术相关的几个基本问题。它还最终证明了该试剂盒作为商业产品的可行性。几位独立用户使用XASK原型成功选择了X-Aptamer，这远远超过了第一阶段的预期结果。 X-适体是化学修饰的DNA亲和剂，其利用氨基酸官能团甚至小分子来增强与靶标的相互作用。XA通常表现出纳摩尔至皮摩尔的结合亲和力以及优异的特异性，使其成为抗体的有希望的合成替代品。AM Biotech开发了一种快速的单循环XA发现过程，该过程不基于SELEX。该过程通过两个简单的步骤进行，使用基于珠的寡核苷酸文库和标准实验室设备，使发现过程包装到XASK中。第二阶段SBIR将侧重于：1）提高至关重要的基于微珠的文库的质量，2）优化基于微珠的选择过程，以将成功率提高到> 85%。XASK是一种革命性的产品，它将颠覆适体市场，并将开始进军抗体市场。AM Biotech认为，XASK和X-Aptamers有望实现强大的市场渗透，这将有助于将适体引入许多商业应用。